Pre-Conference Workshop Day

Tuesday, April 25, 2023

Workshop A: 8:30am-11:30am

8:30 am Translating Novel Neuroinflammatory Molecular Biomarkers to Clinically Detect Levels of Neuroinflammation


As novel neuroinflammatory biomarker research progresses, it is important to assess how these indicators translate in a clinical setting. Uncover key criteria to be met when defining an effective and accurate biomarker of neuroinflammation. Attendees will review how molecular biomarkers are being used presently to detect the neuroinflammatory state of a range of neurological disease areas such as:

  • Multiple Sclerosis
  • Alzheimer's
  • Parkinson's
  • Amyotrophic Lateral Sclerosis

Workshop B: 12:00pm-15:00pm

12:00 pm Advancing Translation of Preclinical Knowledge to Optimize Neuroinflammatory Targeting & Enhance Patient Response

  • Fabrizio Gasparini Executive Director, Head Of Neurodegeneration & Neuroinflammation, Neuroscience Research, Novartis AG
  • Silke Miller Director - Neuroscience Biomarkers, Janssen
  • Irena Kadiu Senior Director, UCB


Translatability is proving one of the biggest barriers for neuroimmunology drugs reaching the clinic. By addressing

the translational limitations exhibited by preclinical neuroglial models, this workshop will provide actionable takeaways to enhance your pipeline of neuroinflammatory targeted therapeutics into trials.

Attendees will discuss in detail:

  • Selecting the right disease pathology to effectively test the target of interest
  • Optimizing the time of intervention during CNS inflammatory progression
  • Determining how therapeutic intervention will impact neuroinflammatory states and how these modulations will be assessed

Workshop C: 08:30am-11:30am

8:30 am Deepening Understanding of Neuroinflammatory Mechanisms to Inform Selection of Novel Targets


Advanced understanding of neuroinflammatory pathways and glial biology will determine future discovery of novel targets. Attendees will learn novel breakthroughs in the pathology and biology of neurological disease, thus aiding the selection of new targets based on recent discoveries.

Attendees will also consider how these advancing scientific findings may translate into novel fields, such as:

  • CNS damage and repair induced by traumatic brain injury or cerebral hemorrhage
  • Neurological consequences associated with COVID and its long-term effects of infection on the CNS

Workshop D: 12:00pm-15:00pm

12:00 pm Exploring New Workflow to Incorporate Human Data, Experimental Evidence & Known Biology for Better Target Identification & Increase of the Probability of Success for Drug Development


Attendees will review current progress on neuroimmunology

drug discovery workflow and discuss:

  • How to properly utilize multi-omics studies, genetics and clinical data for CNS target identification
  • How to perform target screening with utilization of novel CNS experimental models
  • How to prioritize/rank targets based on known CNS disease biology with existing literature and database